Affivant is dedicated to developing novel immuno-oncology approaches to activate and enable the innate immune system to fight cancer. Our innovative bi-specific innate cell engagers are designed to target specific patient populations as powerful monotherapies and combination treatments.

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    10-19
Key business